key: cord-0848404-3fxg89ss
authors: Swan, D.; Enright, H.; Desmond, R.; Le, G.; El Hassadi, E.; Hennessy, B.; Lynott, F.; O'Keeffe, D.; Crowley, M.; Smyth, L.; Perera, K.; Jennings, C.; Ni Ainle, F.; Coll, J.; Ryan, K.; O'Donnell, J.; Lavin, M.; O'Connell, N.
title: Vaccine-induced thrombosis and thrombocytopenia (VITT) in Ireland: A review of cases and current practices
date: 2021-11-10
journal: Thrombosis Update
DOI: 10.1016/j.tru.2021.100086
sha: 2c20ca922dfdaa4cbf51c7b57dcb91d507a5adf9
doc_id: 848404
cord_uid: 3fxg89ss

Since the beginning of the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2) virus pandemic, several highly effective and safe vaccines have been produced at remarkable speed. Following global implementation of vaccination programmes, cases of thrombosis with thrombocytopenia following administration of adenoviral vector-based vaccines started being reported. In this review we discuss the known pathogenesis and epidemiology of so-called vaccine induced thrombocytopenia and thrombosis (VITT). We consider the available guidelines, diagnostic laboratory tests and management options for these patients. Finally, we discuss important unanswered questions and areas for future research in this novel pathoclinical entity.

The Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2) virus pandemic has caused high levels of mortality and morbidity, leading to approximately 4.5 millions deaths world-wide (1). Several vaccines have been developed with unprecedented speed, with four J o u r n a l P r e -p r o o f vaccines approved by early 2021. These vaccines are highly effective at reducing disease incidence and severity, with one vaccine dose reducing risk of hospitalization and death by over 80% (2) .

In March 2021, three groups in Norway, Germany and the United Kingdom, reported the occurrence of thrombotic complications with thrombocytopenia in previously healthy patients who had recently received the AstraZeneca (AZ) ChAdOx1 nCoV-19 vaccine (3) (4) (5) , with further reports in the following weeks and months (6, 7) . A high proportion of cases had thrombosis at unusual sites, in particular, cerebral venous sinus thrombosis (CVST) and This review summarises the current understanding of the pathogenesis and epidemiology of VITT and compares the initial published cases to more recent reports including experience from a cohort of Irish patients. The available guidelines, laboratory testing and management options for VITT are discussed and future areas of research are highlighted.

The similarities in clinical presentation between initial patients with VITT and with heparininduced thrombocytopenia (HIT) led to the recognition that the pathogenesis of both conditions might be similar. The groups who first reported this phenomenon independently identified that affected patients had high circulating levels of immunoglobulin G (IgG) antibodies against platelet factor 4 (PF4), detected by enzyme linked immunosorbent assay (ELISA) (3) (4) (5) . HIT is characterized by thrombosis and thrombocytopenia secondary to J o u r n a l P r e -p r o o f antibodies directed against PF4-heparin complexes, which crosslink FcIIa receptors (FcRIIa) on platelets, causing platelet activation, degranulation and aggregation. FcRIIa is also present on monocytes, endothelial cells and neutrophils. Anti-PF4 binding leads to enhanced tissue factor expression, thrombin generation and formation of neutrophil extracellular traps (NETs), generating a hypercoagulable state (10). Atypical HIT is a rare form of HIT, occurring in the absence of prior heparin exposure, in which the anti-PF4 antibodies are heparin-independent (11) . Similarly, anti-PF4 antibodies in patients with VITT are able to bind to platelets and other cells via FcRIIa receptors, leading to platelet activation, consumption and thrombosis, in the absence of heparin (3) (see Figure 1 ).

The pathogenesis of HIT relies upon the differential electric charges between PF4 and heparin. PF4 is a positively charged cation stored in platelet alpha-granules. PF4 binds to heparin, which is strongly anionic (termed a polyanion), producing a conformational change and exposing a new epitope, thus stimulating autoantibody formation (12) . In patients with VITT, it is hypothesized that anionic surfaces present in adenoviral vector-based vaccines are performing a similar role to heparin in HIT. One group has shown that VITT anti-PF4 antibodies consistently bind within the heparin-binding site of PF4, whereas HIT anti-PF4 antibodies may bind to other sites within PF4. This may partly explain the mechanism by which VITT antibodies mimic the effect of heparin, by binding a similar site on PF4, enabling PF4 tetramers to cluster and form immune complexes, leading to FcRIIa-dependent platelet activation (13).

Greinacher et al. have recently published important results suggesting a two-step mechanism for thrombosis in VITT (14) . In the first step, vaccine components including adenovirus hexon protein, bind to PF4, induce a conformational change and expose a neoantigen. Proinflammatory responses to vaccination amplify antibody production. The AZ vaccine contains EDTA (Ethylenediaminetetraacetic acid), which increases vascular permeability, a hallmark of inflammation (15) . In addition, around 50% of proteins within the AZ vaccine are derived from the T-Rex HEK293 human embryonic kidney-derived production cell line. The immunogenicity of these proteins and impact on inflammation has yet to be established (16) . In the second step, five to 20 days after vaccination, anti-PF4 VITT antibodies have been produced in sufficient quantities to activate platelets and other cellular lineages via FcRIIa receptors.

Thrombi are composed of fibrin, erythrocytes and platelet aggregates. Historically, arterial thrombi were considered to be 'white' clots, comprised mainly of platelets and thus treated with antiplatelet agents, whereas venous thrombi were 'red' clots, made predominantly of fibrin and red cells requiring anticoagulation (17) . VITT is characterized by thrombocytopenia alongside decreased fibrinogen and increased D-Dimers, suggesting involvement of both platelets and the coagulation system. Postmortem analysis of two patients who died as a consequence of extensive thrombosis and intracranial haemorrhage revealed increased complement components on vascular endothelial surfaces, the presence of platelet aggregates lining small and medium sized vessel walls and inflammatory cells, particularly monocytes. These findings indicate further involvement by both the innate immune system and complement activation in the aetiology of thrombosis in VITT (18).

Greinacher et al. showed that incubation of human neutrophils with VITT patient serum induced NETosis in a platelet dependent fashion. Immunohistochemical analysis of samples from CVST in two VITT patients showed abundant activated neutrophils and evidence of enhanced NETosis compared with similar material from a patient with CVST not caused by VITT (14) . The precise interplay between platelet activation, inflammation, the complement system and the coagulation cascade in the pathogenesis of VITT has yet to be elucidated and may be key to optimizing management of these cases in future. Whether these represent true cases of VITT is not certain from the information available (21).

A summary of reported case series is presented in Table 1 (3-6, 8, 23) . Considering five initial case reports, concerning patients identified in March and April 2021, 52 patients are described, 51 of whom received the AZ vaccine and 1 the J&J vaccine (3) (4) (5) (6) 8) . There was a strong female predominance in these first initial reports, ranging from 61% to 100% of cases. The average time between vaccination and symptom onset was between approximately 8-12 days and up to 24 days. CVST was the most frequently observed thrombotic complication followed by SVT. A mean platelet nadir of 30-40 x 10 9 /l was seen across the reports, D-dimers were consistently extremely elevated, at levels higher than usually seen in acute VTE, and hypofibrinogenaemia was found in around half of patients. The mean platelet count on presentation was 106 x 10 9 /l (range 24-258 x 10 9 /l), with a nadir of 89 x 10 9 /l (range 24-230 x 10 9 /l). Mean fibrinogen was 2.6 g/l (median 2.3 g/l), with hypofibrinogenaemia identified in three cases. D-dimers were highly elevated in nine of 10 cases, with an average of >10 mg/l (normal <0.5 mg/l). Particle gel immunoassay screening was poorly sensitive, with only 1 positive result in 5 cases tested, in keeping with other caseseries and published data (25) . PF4 IgG ELISA (Immucor) was strongly positive in all 10 cases.

The mean OD was 2.3 (upper limit of normal 0.352 OD), with nine of 10 cases having an OD > 2, and all samples showing strong inhibition by heparin (mean 99%). The HIPA was positive in three out of 10 cases, whereas the PIPA was positive in 9 of 10 cases (1 negative sample was subsequently positive on retesting following optimisation of the assay, the patient was treated as presumed VITT prior to confirmation of a positive PIPA).

In comparison with the first case series published, our cohort have a higher platelet count, an equal sex distribution, fewer CVSTs and no mortality. A recent, larger publication of 220 definite or probable VITT cases from the UK reported a slight female excess of 55%, median age of 48 years and a median platelet count of 47 x 10 9 /l. CVST occurred in 50% and Ddimers were markedly elevated. Mortality was 22% overall and 73% in patients with a baseline platelet count of <30 x 10 9 /l with concomitant intracranial haemorrhage (ICH) (23) .

Data from the MHRA have also reported no clear sex predominance, with 51% of 417 cases being female, and a rate of CVST of 36%, similar to our findings. Average age was 46 years for those with CVST and 54 years for other cases, however patients were affected up to the age of 93 years (21). Mortality in the 417 cases was 17%, far lower than rates initially reported.

It has been suggested that the over-representation of female cases in initial reports may reflect differences in national rollout schedules. Norway and Germany concentrated on J o u r n a l P r e -p r o o f early vaccination of healthcare workers, who are disproportionately female (26) . Discrepant mortality rates may reflect variable rates of CVST within studies, and the now heightened awareness and prompt treatment of this condition. Pavord et al. showed that mortality was associated with CVST and worsening coagulopathy. Hazard ratios (HR) for mortality were increased in the presence of certain clinical features including CVST (HR 2.7, 95% confidence interval [CI] 1.4-5.2), every 50% decrease in platelet count (HR 1.7, 95% CI 1.3-2.3), every 10,000 mcg/l increase in D-Dimer (HR 1.2, 95% CI 1.0-1.3) and every 50% decrease in baseline fibrinogen level (HR 1.7, 95% CI, 1.1-2.5) (23). Initial cases were very advanced before VITT was recognized, leading to a higher proportion of patients with severe disease manifestations such as marked thrombocytopenia, coagulopathy and ICH, which may account for the higher mortality rates seen initially in comparison to recent publications and the experience in Ireland.

Following the identification of VITT, several bodies have rapidly formulated and released guidelines regarding diagnosis and management. Perhaps unsurprisingly, given the limited available information on which to form these recommendations, significant differences exist between documents, and a number of recommendations have been amended since initial release (27-33). A summary of the available guidelines is presented in Table 2 . 

Patients who warrant further investigation should have samples sent for confirmatory lab testing. There are several tests used to confirm the presence of clinically relevant HIT antibodies. These differ in various technical aspects including the source of PF4 and polyanion used, which alter their ability to reliably detect VITT antibodies. Serum samples from 12 patients with confirmed VITT by functional testing were used to assess the utility of three ELISA tests (Immucor, Hyphen and Stago), a particle gel immunoassay (PaGIA), a chemiluminescence immunoassay (CLIA) and lateral flow immunoassay (LFA). The PF4

ELISAs performed well, with calculated sensitivities of 100%, 92% and 91% for the respective assays. PaGIA, CLIA and LFA had sensitivities of <1% and should not be used to screen suspected VITT (25) . A functional test is subsequently required to confirm that the VITT antibodies detected lead to platelet aggregation in vitro. Available tests include a modified HIPA test with the addition of PF4 (PIPA) (3), heparin-induced multiple electrode aggregometry (HIMEA) (4) and SRA, which had poor specificity in the report by See et al. but has been used successfully elsewhere (6) . There are also flow cytometry-based tests, such as the PF4-induced flow cytometry-based platelet activation assay (PIFPA) (34) and the 'procoagulant platelets' test, which uses annexin V as a flow cytometric marker of donor platelet activation following exposure to patient serum (35) . These tests vary in their requirement for washed platelet or whole blood, serum or plasma, and volume of sample (summarized in Table 3 ). They are highly specialized and should only be performed by experienced centres, with choice of test dependent on available expertise.

Patients with suspected or confirmed VITT should be treated without delay. We next discuss the therapies recommended or suggested by the published guidelines, and the relevant supporting evidence. The mainstay of treatment comprises intravenous immunoglobulins and non-heparin anticoagulation.

Greinacher et al. demonstrated that PF4-dependent platelet activation in VITT is mediated by binding to FcRIIa. Platelet activation was inhibited by both the anti-FcRIIa monoclonal antibody IV.3, and by the addition of IVIg (Privigen) (3) . Three VITT patients with predominantly arterial thrombosis received IVIg with consistent platelet increments in platelet count seen in two, and an initial response in the third. IVIg treatment did not significantly impact ELISA OD results, indicating lack of inhibition of VITT antibody binding to PF4. IVIg did however lead to reduced reactivity by SRA in the presence of PF4, demonstrating a reduction in the functional ability of VITT antibodies to induce platelet aggregation following IVIg treatment (36) . Based on current evidence, IVIg is the treatment most likely to modify disease course. The majority of guidelines recommend 2 doses of 1g/kg (NICE suggests 1 dose with clinical review). The EHP advise IVIg irrespective of degree of thrombocytopenia (30), Thrombosis Canada have advised its use in severe or lifethreatening thrombosis (28), and the ISTH recommend in cases with a platelet count of < 50

x 10 9 /l (27).

The available guidelines are consistent in recommending the use of non-heparin anticoagulants in patients with thrombosis. Whether heparin adversely affects outcomes in VITT is not definitively known. An early publication described worsened thrombosis in one patient receiving heparin (5) . A review of 70 patients with VITT and CVST reported reduced death or dependency in patients who received non-heparin anticoagulants (36% of 50 patients) compared with those who did not (75% of 20 patients) (37) . Conversely, the recent larger UK dataset reported a mortality rate of 20% in patients treated with heparin, versus 16% in those who received alternate anticoagulants. The authors of this review concluded that heparin did not appear harmful (23) . However, the sample size in these publications is small, and until it is conclusively known whether heparin is safe in patients with VITT, its use is not recommended. Suitable alternatives, which have proven safe and effective in HIT include parenteral direct thrombin inhibitors argatroban and bivalirudin, direct oral anticoagulants without a heparin lead-in phase (apixaban and rivaroxaban), fondaparinux or danaparoid (38) . Therapeutic dose anticoagulation is safe in patients with a platelet count of 50 x 10 9 /l or higher (39) .

Whether therapeutic anticoagulation is required in patients with VITT without documented thrombosis, similar to patients with HIT, is not certain. The NICE guidelines and EHP suggest consideration of non-heparin VTE prophylaxis in patients with VITT without confirmed thrombosis, but with thrombocytopenia and D-Dimers >4000 mcg/l (30, 33). The other guidelines do not discuss VTE prophylaxis in suspected VITT patients.

Historically, HIT was thought to be a prothrombotic condition in which bleeding was a rare manifestation. Although this belief has been challenged in recent years (40), the rate of haemorrhagic complications in VITT patients seems to be higher than seen previously in the setting of HIT. This is particularly true of those with CVST, in which ICH may be seen in up to 80% of cases, with high associated morbidity and mortality (3) (4) (5) (6) . Blood product support to manage coagulopathy may therefore be more important in this novel disease entity.

Fibrinogen levels should be maintained at 1.5 g/l or higher using fibrinogen concentrate or cryoprecipitate depending on national and local policy. Platelet transfusions have been associated with increased thrombosis and mortality rates in HIT, although this remains an area of debate (41, 42) . At the time of writing, it is unclear whether platelet transfusions will exacerbate the pathogenesis of VITT. As such, they are not recommended routinely, but may be considered in thrombocytopenic patients requiring neurosurgery and in the context of active bleeding (31). Reduced 'critical care' dosing of argatroban is an option in patients with a platelet count < 50 x 10 9 /l as an alternative to transfusing platelets in order to facilitate full therapeutic dose anticoagulation (30).

Whether corticosteroids are beneficial in VITT is unknown. There are case reports showing benefit in patients with HIT (43, 44) , and the combination of IVIg with methylprednisolone raises platelet counts faster in childhood ITP, another autoantibody-mediated condition, than IVIg alone (45) . NICE recommends corticosteroids if IVIg treatment is insufficient, the ISTH advocates their use in patients with a platelet count <50 x 10 9 /l, and the EHP guidelines suggest upfront corticosteroids in patients with CVST due to high mortality rates amongst this cohort (27, 30, 33).

Plasma exchange may be of benefit. A 90% survival rate was reported following use of plasma exchange in 17 patients with CVST and/or extensive thrombosis, using solvent detergent plasma (Octaplas). The two deaths were both in patients with intracranial haemorrhage at presentation (23) . Successful use of plasma exchange was also reported in three cases of persistent thrombocytopenia and progressive thrombosis despite IVIg (46) .

The UK EHP recommends early plasma exchange in those with extensive thrombosis and a platelet count <30 x 10 9 /l (30). The ISTH recommendations are for patients with refractory thrombocytopenia (platelets <30 x 10 9 /l) after IVIg and steroids (27).

There is no evidence that the anti-CD20 monoclonal antibody Rituximab improves outcomes in VITT, with anecdotal use in HIT only (47) . The UK guidelines both suggest consideration of rituximab in patients refractory to IVIg and plasma exchange, although there is no evidence to support this approach at the current time (30, 33).

Activation of complement in VITT has been demonstrated in post-mortem findings (18) .

Eculizumab, a monoclonal antibody directed against complement C5, prevents terminal complement activation. A case report describes its use in two cases of VITT, one with thrombotic microangiopathy and renal failure, and the other with a severe thromboembolic event following IVIg administration (48) . The ASH guidelines include eculizumab as a treatment option, however supportive evidence is lacking (31).

The astute observation of acute thrombosis and thrombocytopenia after vaccination with adenoviral vector-based SARS CoV-2 virus vaccines, and the subsequent description and characterization of VITT happened with great rapidity. At the time of writing, much remains unknown, including the pathogenesis of the antibody response against PF4, the varying prevalence of VITT following vaccination with the AZ versus J&J vaccine, the reason for disproportionate numbers of CVST and SVT in cases of VITT, and the risk associated with revaccination. The majority of cases have occurred following the first vaccine dose (89% in the MHRA report (21)). Data is awaited on outcomes for these patients after a second vaccine dose with an mRNA-based vaccine. Although VITT is thought to be primarily mediated by platelet activation, anti-platelet agents are not recommended by the available guidelines due to concerns regarding increased bleeding risk and unclear evidence of potential benefit (27-31, 33). One group assessed the ability of serum from four confirmed VITT cases to induce platelet aggregation in the presence of the COX inhibitor indomethacin and the P2Y12 inhibitor ticagrelor. Both these agents, as well as heat inactivation of sera, impaired aggregation, which the authors hypothesized might reflect a contribution from complement (53) . Aspirin has been shown to only partly inhibit platelet aggregation induced by anti-PF4 antibodies in serum from patients with HIT (54), and is not recommended as part of the treatment of either HIT or VITT (55) . One hypothesis considers the structure of clots, whereby a core of highly activated platelets is surrounded by a looser shell of less activated platelets. Thrombin activity and fibrin formation are found mainly in the densely packed core, where close proximity means fibrinogen is better able to bind to platelet glycoprotein (GP) IIb/IIIa (56) . It has been postulated that perhaps platelet activation is so robust in VITT that dense clots are formed within circulatory beds, consuming platelets and fibrinogen via GPIIb/IIIa, producing the picture of thrombosis and coagulopathy observed (57) . Addition of the GPIIb/IIIa inhibitor eptifibatide to donor platelets treated with VITT serum inhibits aggregation (53), however use of such potent antiplatelet agents in clinical practice would likely be associated J o u r n a l P r e -p r o o f with an unacceptable bleeding risk. At the current time, the value of antiplatelet therapy in management of VITT is unproven.

The effects of inhibitors of FcRIIa and its downstream signaling pathways on platelet aggregation in VITT were also analysed. Platelet activation was abolished by the monoclonal antibody IV.3 as seen previously (3), but also by the Src (sarcoma genes tyrosine kinases) inhibitor dasatinib, the Syk (spleen tyrosine kinase) inhibitor entosplentinib and the Btk (bruton tyrosine kinase) inhibitors ibrutinib and rilzabrutinib (53) . Further consideration of the cellular pathways involved in this condition may shed light on how to optimize future treatment strategies.

Another important question concerns duration of anticoagulation. VTE in patients with HIT is considered to be provoked by a transient reversible risk factor, warranting 3 months of therapeutic anticoagulation (55) . Consensus regarding duration of anticoagulation in patients with HIT without thrombosis has not been reached, with recommendations ranging from until resolution of thrombocytopenia to 4-6 weeks (58). It seems reasonable to treat patients with VITT and proven thrombosis for a minimum of 3 months. However whether it is safe to discontinue anticoagulation after this period in cases with persistent evidence of 

There are no conflicts of interest 

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative casecontrol study

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination

Successful treatment of vaccine-induced prothrombotic immune thrombocytopenia (VIPIT)

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination

Thrombosis With Thrombocytopenia After the Messenger RNA-1273 Vaccine

Heparin-Induced Thrombocytopenia: A Focus on Thrombosis

Autoimmune heparin-induced thrombocytopenia

Heparin-induced thrombocytopenia (HIT): Review of incidence, diagnosis, and management

Antibody epitopes in vaccineinduced immune thrombotic thrombocytopaenia

Insights in ChAdOx1 nCov-19 Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT)

Reversibility of increased microvessel permeability in response to VE-cadherin disassembly

HEK293 in cell biology and cancer research: phenotype, karyotype, tumorigenicity, and stress-induced genome-phenotype evolution

Venous and Arterial Thromboses: Two Sides of the Same Coin?

Post-mortem findings in vaccine-induced thrombotic thombocytopenia

Vaxzevria (previously COVID-19 Vaccine AstraZeneca)

Kingdom GotU. Coronavirus vaccine-weekly summary of Yellow Card reporting

Response CfDCaPEPa

Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis

Vaccine-induced immune thrombotic thrombocytopenia (VITT) -a novel clinico-pathological entity with heterogeneous clinical presentations

PF4-Dependent Immunoassays in Patients with Vaccine-Induced Immune Thrombotic Thrombocytopenia: Results of an Interlaboratory Comparison

Vaccine-induced Immune Thrombocytopenia and Thrombosis (VITT)

Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH

Covid-19 Vaccine-induced Immune Thrombocytopenia and Thrombosis (VITT)

Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: Communication from the ISTH SSC Subcommittee on Platelet Immunology

A flow cytometric assay to detect platelet-activating antibodies in VITT after ChAdOx1 nCov-19 vaccination

Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia

Adjunct Immune Globulin for Vaccine-Induced Immune Thrombotic Thrombocytopenia

Cerebral venous thrombosis after vaccination against COVID-19 in the UK: a multicentre cohort study

Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review

Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus

Platelet transfusions in platelet consumptive disorders are associated with arterial thrombosis and in-hospital mortality

Outcomes after platelet transfusion in patients with heparin-induced thrombocytopenia

Treatment of refractory delayed onset heparin-induced thrombocytopenia after thoracic endovascular aortic repair with intravenous immunoglobulin (IVIG)

Refractory Heparin-Induced Thrombocytopenia With Cerebral Venous Sinus Thrombosis Treated With IVIg, Steroids, and a Combination of Anticoagulants: A Case Report

IVMP+IVIG raises platelet counts faster than IVIG alone: results of a randomized, blinded trial in childhood ITP

Therapeutic Plasma Exchange in Vaccine-Induced Immune Thrombotic Thrombocytopenia

Refractory heparin induced thrombocytopenia with thrombosis (HITT) treated with therapeutic plasma exchange and rituximab as adjuvant therapy

Prothrombotic immune thrombocytopenia after COVID-19 vaccination

An observational study to identify the prevalence of thrombocytopenia and anti-PF4/polyanion antibodies in Norwegian health care workers after COVID-19 vaccination

Understanding VITT(ual) reality

Frequency of positive anti-PF4/polyanion antibody tests after COVID-19 vaccination with ChAdOx1 nCoV-19 and BNT162b2

The association of anti-platelet factor 4/heparin antibodies with early and delayed thromboembolism after cardiac surgery

Platelet Activation by Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) Patient Serum is Blocked by COX, P2Y<sub>12</sub> and Kinase Inhibitors

Heparin-induced thrombocytopenia: further studies of the effects of heparin-dependent antibodies on platelets

Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition

Hierarchical organization in the hemostatic response and its relationship to the plateletsignaling network

COVID-19 Vaccine-Induced Immune Thrombosis with Thrombocytopenia (VITT) and the Shades of Grey in Thrombus Formation

American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia

Decline in Pathogenic Antibodies over Time in VITT

UK EHP D+5 to +30 ( or +42 if isolated DVT or PE) Acute thrombosis Plts <150 × 10 9 /l Positive anti-PF4 ELISA D-Dimer >4000 mcg/l D-Dimer >4000 mcg/l but one criterion not fulfilled (